The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV

The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV

Bibliographic Details
Main Author:	Hitchcock CA
Format:	Article
Language:	English
Published:	BMC 2005-12-01
Series:	Retrovirology

Similar Items

Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
by: María Rosa López-Huertas, et al.
Published: (2017-05-01)

Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model.
by: Laura Ochoa-Callejero, et al.
Published: (2013-01-01)

In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
by: Pasqua Gramegna, et al.
Published: (2011-01-01)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
by: Ngoc Dung Le, et al.
Published: (2022-07-01)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists <it>in vitro </it>has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
by: Westby Mike, et al.
Published: (2011-11-01)

A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
by: C Preston Neff, et al.
Published: (2011-01-01)

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure
by: Yasuhiro Ishihara, et al.
Published: (2022-07-01)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
by: Maximiliano Ruben Ferrero, et al.
Published: (2021-06-01)

Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.
by: Borislav Savkovic, et al.
Published: (2012-01-01)

T005 (0077) TRABECTEDIN INHIBITS CLASSICAL HODGKIN LYMPHOMA GROWTH, MONOCYTES IMMUNOSUPPRESSIVE POLARIZATION BY TUMOR CELLS AND SYNERGIZES WITH THE CCR5-ANTAGONIST MARAVIROC
Published: (2018-10-01)

Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)

Effectiveness and cost of treatment with maraviroc in HIV infection
by: Viola Sacchi, et al.
Published: (2009-01-01)

Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly
by: Hualiang Jiang, et al.
Published: (2008-10-01)

Bemerkungen zum Sangallensis 857
by: Michael Redeker
Published: (2023-08-01)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015-10-01)

CCR5 Antagonist and Agonist Binding Site Structures
by: Mills John, et al.
Published: (2005-12-01)

Antagonist of chemokine receptors CCR1 and CCR3
by: Ammit Alaina, et al.
Published: (2000-11-01)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016-01-01)

Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas
by: Wilfredo Alejandro González-Arriagada, et al.
Published: (2022-12-01)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
by: Schols Dominique, et al.
Published: (2011-10-01)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
by: Poizot-Martin Isabelle, et al.
Published: (2010-05-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)

Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
by: S. Bowler, et al.
Published: (2019-09-01)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
by: Christophe Rodriguez, et al.
Published: (2015-01-01)

6.857 Network and Computer Security, Fall 2003
by: Rivest, Ronald
Published: (2003)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis.
by: Eric Lefebvre, et al.
Published: (2016-01-01)

Evolution of Multiple Domains of the HIV-1 Envelope Glycoprotein during Coreceptor Switch with CCR5 Antagonist Therapy
by: Yueqi Du, et al.
Published: (2022-08-01)

P427: Withdrawn
Published: (2024-01-01)

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
by: Ai Kawana-Tachikawa, et al.
Published: (2014-01-01)

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis
by: Tobias Puengel, et al.
Published: (2022-06-01)

Design, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.
by: Tao Liu, et al.
Published: (2013-01-01)

Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study.
by: Gugan Kothandan, et al.
Published: (2012-01-01)

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
by: Ungashe, S, et al.
Published: (2008)

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.
by: Carolina Gutiérrez, et al.
Published: (2011-01-01)

Lack of effect of Maraviroc intensification on blood and gut reservoir.
by: Tiraboschi, J, et al.
Published: (2016)

857 Dose- and time-dependent immune cell dynamics in irradiated gliomas
by: Michael Platten, et al.
Published: (2023-11-01)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
by: Jintanat Ananworanich, et al.
Published: (2015-04-01)

Crystal structure and magnetic properties of LaCa0.143 (4)O0.857 (4)F0.143 (4)Bi0.857 (4)S2
by: Rongtie Huang, et al.
Published: (2016-06-01)